Farhad Parhami
Company: MAX BioPharma
Job title: President & CEO
Seminars:
Developing a Novel Small Molecule Oxysterol as a Potent Inhibitor of TGF-β 2:30 pm
Utilizing Oxy210 as a poly-pharmacological drug candidate to target 3 main signaling pathways in fibroblasts and other cells involved in fibrosis and inflammation Demonstrating the intact TGF-β-mediated immune cell responses upon Oxy210 treatment Evaluating the therapeutic effects of Oxy210 on chronic inflammatory diseases associated with metabolic dysfunction New Data!Read more
day: Conference Day Two
Fireside Chat: Assessing the TGF-β Landscape & Predicting Future Innovations 9:30 am
Exploring the current clinical successes of TGF-β targeted therapies Discussing the changes in the TGF-β field with the pivot to fibrosis research Looking to the future for developing TGF-β directed therapies and exciting new technologies using TGF-βRead more
day: Conference Day One